Subcutaneous vs intravenous administration of trastuzumab in HER2+ breast cancer patients: a montenegrin cost-minimization analysis
V Todorovic, I Durutovic, A Ivanovska… - Value in …, 2017 - valueinhealthjournal.com
Objectives The aim of this economic analysis is to compare the total cost of subcutaneous
trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2-positive breast
cancer patients at the Oncology Department at Clinical Center of Montenegro. HannaH
study showed that SC-TRA has a pharmacokinetic profile and efficacy non-inferior to
standard IV-TRA and is a valid alternative for the treatment of eligible breast cancer patients.
Methods A cost-minimization analysis was performed using data from market research from …
trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2-positive breast
cancer patients at the Oncology Department at Clinical Center of Montenegro. HannaH
study showed that SC-TRA has a pharmacokinetic profile and efficacy non-inferior to
standard IV-TRA and is a valid alternative for the treatment of eligible breast cancer patients.
Methods A cost-minimization analysis was performed using data from market research from …
Subcutaneous vs intravenous administration of trastuzumab in HER2+ breast cancer patients: a Macedonian cost-minimization analysis
A Nestorovska, Z Naumoska… - Value in …, 2015 - valueinhealthjournal.com
Objectives The aim of this study is to compare the total cost of subcutaneous trastuzumab
(SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer patients from the R.
Macedonia. Recent studies suggest that SC-TRA has a pharmacokinetic profile and efficacy
non-inferior to standard IV-TRA and is a valid alternative for the treatment of eligible breast
cancer patients. Methods A cost-minimization analysis was performed using data from prior
prospective time-motion study. Total time and cost of both types of TRA administration were …
(SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer patients from the R.
Macedonia. Recent studies suggest that SC-TRA has a pharmacokinetic profile and efficacy
non-inferior to standard IV-TRA and is a valid alternative for the treatment of eligible breast
cancer patients. Methods A cost-minimization analysis was performed using data from prior
prospective time-motion study. Total time and cost of both types of TRA administration were …
以上显示的是最相近的搜索结果。 查看全部搜索结果